Vancouver, British Columbia, September 28, 2021. - Lexston Life Sciences Corp. (CSE:LEXT) (the “Company” or “Lexston”) is pleased to announce that further to the news of July 7th, 2021 announcing the acquisition of 750,000 Class C Non-Voting Common Shares for a total of 13% ownership of Psy Integrated Health Inc. (“Psy Integrated”), Psy Integrated has celebrated their grand opening of its state of the art health and wellness center, Empower Health Clinic, in Vancouver, British Columbia on September 18, 2021.
Empower Clinic will be among the first health and wellness facilities in Canada to offer Psychedelic Assisted Therapy that includes Ketamine Assisted Therapy for treating individuals with mental health issues, mood disorders and chronic pain issues. Psy Integrated’s facility, also offers multidisciplinary psychedelic integration services, addiction services, trauma therapy, and neurotherapy.
In addition to the current health and wellness services being performed, Psy Integrated fully intends to expand their psychedelic assisted therapy programs to include Psilocybin and Methylenedioxymethamphetamine (MDMA) as the legal framework in Canada is developed to allow for it.
Initially established as a stand-alone organization, Empower Health now functions as a clinic brand of Psy Integrated Health Inc., a public benefit company founded in British Columbia on a unique approach to clinic management services, dedicated to fostering collaboration and support among locally owned integrated health clinics.
“Lexston is proud to be in partnership with such a progressive organization which is amongst the leading groups with Psychedelic Assisted Therapy in this country.” states Jag Bal, CEO of Lexston “The important work that Psy Integrated is doing, aligns with many of our own stated goals and objectives, including setting up clinical trials of novel formulations as well as uncovering the pharmacogenomics of psychedelic therapies.”
About Lexston Life Sciences Corp.
Lexston Life Sciences Corp. is a Canadian biotechnology company providing cannabis testing and research services. Lexston is also in the process of securing licensing under the exemptions prescribed by section 56 of the Controlled Drugs and Substances Act (Canada) to enable the expansion of its services into the psychedelic industry with an initial focus on the detection and quantification of psychedelic molecules in the lab and point of care. Lexston intends to develop and validate methods for standardized manufacturing of plant derived psychedelics in support of burgeoning trials in the field of mental health and wellness.
929 Mainland Street
Vancouver, BC V6B 1S3
On Behalf of the Board of Directors
Lexston Life Sciences Corp.
Jagdip Bal Chief Executive Officer
Telephone: (604) 928-8913
This release includes forward-looking information within the meaning of Canadian securities laws regarding Lexston and Psy Integrated and their respective businesses. Such statements are based on the current expectations and views of future events of the management of each entity and are based on assumptions and subject to risks and uncertainties. Although the management of each entity believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release could differ materially as a result of known and unknown risk factors and uncertainties affecting the companies, including market conditions, economic factors, management's ability to manage Lexston and Psy Integrated and the equity markets generally.
Although Lexston and Psy Integrated have attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in the forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Lexston and Psy Integrated do not undertake any obligation to publicly update or revise any forward-looking statement, whether because of new information, future events, or otherwise.
Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.